New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareP21 vs Testagen

P21 vs Testagen

Side-by-side comparison of key properties, dosing, and research.

Cognitive EnhancementAnti-Aging & Longevity
P21
Anti-Aging & Longevity
Testagen
Summary
P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
Testagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Gly) developed by Professor Vladimir Khavinson, tissue-specific for the testes. It supports Leydig cell function, normalization of testosterone biosynthesis, and spermatogenic activity. Testagen is used in men's health protocols for age-related testosterone decline, male fertility support, and testicular anti-aging.
Half-Life
Not well characterized; likely short, but neurogenic effects persist long after administration
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ, Intranasal
SubQ, Oral
Research
Typical Dose
100–500 mcg
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Promotes hippocampal neurogenesis
  • Enhances spatial memory and learning
  • Increases BDNF expression
  • Reduces amyloid-beta plaque formation (animal models)
  • Anti-tau pathology potential
  • Cognitive enhancement without stimulant effects
  • Potential therapeutic for Alzheimer's and cognitive aging
  • Supports endogenous testosterone synthesis via Leydig cell normalization
  • Promotes spermatogenesis and sperm quality
  • Anti-aging effects on testicular tissue
  • May attenuate age-related testosterone decline
  • Mechanistically distinct from TRT — does not suppress HPG axis
  • Useful adjunct to Gonadorelin and Kisspeptin-10 in male hormonal protocols
  • Supports male fertility without exogenous hormone replacement
Side Effects
  • Generally well tolerated in animal studies
  • Limited human clinical data
  • Injection site reactions
  • Potential mild fatigue at initiation
  • Generally well tolerated
  • Mild injection site reactions
  • No significant endocrine disruption reported at standard doses
Stacks With